In vivo spectroscopic photoacoustic imaging and laser‐induced nanoparticle vaporization for anti‐HER2 breast cancer

This study reports on the development and application of theragnostic agents targeting the HER2 receptors in breast tumors. The agent was constructed by loading silica‐coated gold nanorods (GNRs) and a perfluorohexane liquid into PLGA‐PEG nanoparticles, followed by surface conjugation with antibody Herceptin. The particle uptake in human breast cancer MDA‐MB‐231 (HER2‐negative) and BT474 (HER2‐positive) cell lines was tested. A proof of principle in vivo study was also performed using a xenograft mouse bilateral tumor model (16 mice, 32 tumors). Photoacoustic imaging was performed using a VevoLAZR device at 720/750/850 nm illuminations and 21 MHz central frequency. The relative concentrations of GNRs in the tumor were quantified using a linear spectral unmixing technique. The therapeutic efficacy of these nanoparticles was evaluated through optical droplet vaporization, and cell damage was confirmed using tissue immunofluorescence and histology. Our results demonstrate the potential of PLGA‐GNRs as theragnostic agents for anti‐HER2 breast cancer therapy. This study reports on the development and application of theragnostic agents targeting the HER2 receptors in breast tumors. Photoacoustic imaging and a linear spectral unmixing technique were performed to monitor the longitudinal nanoparticle uptake in tumors. The therapeutic efficacy of these nanoparticles was evaluated through optical droplet vaporization. Our results demonstrate the potential of these nanoparticles as photoacoustic imaging and therapeutic agents for anti‐HER2 breast cancer in biomedical research.